Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Alessandra Risso et al.|Cancer|2011Cited by 28
Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluationSilvia Gaia, Corrado Tarella, Antonella Olivero et al.|Hepatology International|2013Cited by 21
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.Anna Guidetti, Alessandro M. Gianni, Alessandra Risso et al.|Blood|2010Cited by 1